Pharmacokinetic Alteration of 99mTc-MAG3 using Serum Protein Binding Displacement Method

Nuclear Medicine and Biology

Volumn 40, Issue 3, 2013, Pages 366-370

  Nishi, Kodai ^a   Kobayashi, Masato ^a   Nishii, Ryuichi ^b   Shikano, Naoto ^c   Takamura, Norito ^d   Kuga, Noriyuki ^a,b   Yamasaki, Keishi ^e   Nagamachi, Shigeki ^b   Tamura, Shozo ^b   Otagiri, Masaki ^e   Kawai, Keiichi ^a,f  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c IBARAKI PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^d KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e SOJO UNIVERSITY   (Japan)

^f UNIVERSITY OF FUKUI   (Japan)

Author keywords

99mTc MAG3; Competitive displacement; Pharmacokinetics; Renogram; Serum protein binding

Indexed keywords

BUCOLOME; CEFAZOLIN; HUMAN SERUM ALBUMIN; IBUPROFEN; MERTIATIDE TC 99M; OCTANOIC ACID; OLEIC ACID; VALPROIC ACID; WARFARIN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BINDING AND RELATED PHENOMENA; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HUMAN; ISOTOPE LABELING; MALE; NONHUMAN; RAT; RENOGRAPHY; SERUM PROTEIN BINDING DISPLACEMENT METHOD; ULTRAFILTRATION;

ANIMALS; BINDING, COMPETITIVE; HUMANS; MALE; PROTEIN BINDING; RATS; RATS, WISTAR; SERUM ALBUMIN; TECHNETIUM TC 99M MERTIATIDE;

EID: 84875260007     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.12.002     Document Type: Article

References (22)

1. Jephers O., Piepsz A., Ham H.R. What does protein binding of radiopharmaceuticals mean exactly?. Eur J Nucl Med 1990, 17:101-102.
2. Berridge M.S. The importance of kinetic enhancement. J Nucl Med 2009, 50:1203-1204.
3. Martin B.K. Potential effect of the plasma on medicine distribution. Nature 1965, 207:274-276.
4. Meyer M.C., Guttman D.E. The binding of medicines by plasma proteins. J Pharm Sci 1968, 57:895-918.
5. Vallner J.J. Binding of medicines by albumin and plasma protein. J Pharm Sci 1977, 66:447-465.
6. 123I-N-isopropyl-p-iodoamphetamine. Nucl Med Biol 2009, 36:99-106.
7. 123I-iodoamphetamine. J Nucl Med 2009, 50:1378-1383.
8. Bubeck B., Brandau W., Weber E., Kälble T., Parekh N., Georgi P. Pharmacokinetics of technetium-99m-MAG3 in humans. J Nucl Med 1990, 31:1285-1293.
9. Kawai K, Takamura N, Nishii R. Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method. United States Patent 2006; US 7,029,653.
10. Takamura N., Haruta A., Kodama H., Tsuruoka M., Yamasaki K., Suenaga A., et al. Mode of interaction of loop diuretics with human serum albumin and characterization of binding site. Pharm Res 1996, 13:1015-1019.
11. Takamura N., Maruyama T., Ahmed S., Suenaga A., Otagiri M. Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm Res 1997, 14:522-526.
12. Otagiri M. A molecular functional study on the interactions of medicines with plasma proteins. Drug Metab Pharmacokinet 2005, 20:309-323.
13. Muller-Suur R., Muller-Suur C. Glomerular filtration and tubular secretion of MAG-3 in the rat kidney. J Nucl Med 1989, 30:1986-1991.
14. 99mTc-MAG3: pharmacokinetics and slope clearance determination. Contrib Nephrol 1990, 79:72-73.
15. 99mTc renal tubular function agents: current status. Semin Nucl Med 1990, 20:28-40.
16. Gonzalez A., Ros D., Pavia J. Estimate of relative function and transit time in renographic studies. J Nucl Biol Med 1994, 38:502-507.
17. Ozcan Z., Anderson P.J., Gordon I. Assessment of regional kidney function may provide new clinical understanding and assist in treatment of children with prenatal hydronephrosis. J Urol 2002, 168:2153-2157.
18. Yashiki T., Matsuzawa T., Yamada M., Kondo T., Mima H. Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. V. Pharmacokinetics of BCP in man and in rabbit following intravenous administration of BCPNa. Chem Pharm Bull(Tokyo) 1971, 19:881-891.
19. Yashiki T., Matsuzawa T., Yamada M., Kondo T., Uda Y. Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. IV. Pharmacokinetics of BCL in man following oral administration. Chem Pharm Bull(Tokyo) 1971, 19:869-880.
20. Tsurumi K., Abe A., Nozaki M., Fujimura H. Influence of some anti-inflammatory, antipyretic and analgesic agents on urinary enzyme level in rats. J Toxicol Sci 1978, 3:1-9.
21. Chiba K., Yoshida M., Ishihara A., Sudo J., Tanabe T., Miyazaki S., et al. Study of interactions between ibuprofen and sulfonamides, and between BCP and sulfonamides in rats. Chem Pharm Bull(Tokyo) 1985, 33:3415-3421.
22. Sato H., Tawaraya H., Takagi A., Wakabayashi M., Yoshida K., Ueno M., et al. A case of heterozygous protein C deficiency associated with nephrotic syndrome and deep femoral artery thrombosis. Nippon Jinzo Gakkai Shi 1991, 33:327-332.